Isocitrate Dehydrogenase Inhibitors Market Size, IDH1/IDH2 Drugs, Pipeline & Forecast 2035

Isocitrate Dehydrogenase Inhibitors Market Size & Forecast 2035

The global isocitrate dehydrogenase inhibitors market was valued at US$3.80 billion in 2025 and is projected to reach US$10.69 billion by 2035, growing at a CAGR of 10.9% during 2026-2035. Growth is being driven by broader molecular testing in acute myeloid leukemia, commercial expansion of IDH-targeted therapy into glioma, increasing use of IDH inhibitors in treatment combinations, and clinical development in myelodysplastic syndromes, chondrosarcoma, and other IDH-mutant tumors.

The largest structural change in the market is the creation of a CNS-targeted IDH inhibitor segment. FDA approved vorasidenib in August 2024 for adults and adolescents aged 12 years and older with Grade 2 IDH1- or IDH2-mutant astrocytoma or oligodendroglioma after surgery. It became the first FDA-approved systemic treatment for this specific Grade 2 IDH-mutant glioma population.

The market is therefore moving beyond its original concentration in IDH-mutant AML. Commercial opportunity now spans hematologic malignancies, biliary tract cancer, and molecularly defined brain tumors, with new programs aiming to move IDH inhibition into high-grade glioma, post-vorasidenib disease, frontline AML combinations, and IDH1-mutant chondrosarcoma.

Isocitrate Dehydrogenase Inhibitors Market Highlights

• 2025 Market Size: US$3.80 Billion
• 2035 Market Size: US$10.69 Billion
• CAGR, 2026-2035: 10.9%
• Largest Region: North America, with 44.6% market share in 2025
• Fastest-Growing Region: Asia-Pacific
• Leading Drug Segment: IDH1 Inhibitors, with 52.3% market share in 2025
• IDH2 Inhibitor Share: 38.4% in 2025
• Dual IDH1/IDH2 Inhibitor Share: 9.3% in 2025
• Largest Application: Acute Myeloid Leukemia, with 58.7% market share in 2025
• Second-Largest Application: Cholangiocarcinoma, with 22.4% market share in 2025
• Glioma Share: 11.3% in 2025, with the strongest application-level growth outlook
• Key Growth Areas: Grade 2 IDH-mutant glioma, post-vorasidenib treatment, frontline AML combinations, IDH1-mutant MDS, chondrosarcoma, first-line cholangiocarcinoma combinations and companion diagnostics.

Why Vorasidenib Changed the Commercial Structure of the IDH Inhibitor Market

For several years, IDH inhibitor revenue was built primarily around AML and, later, IDH1-mutant cholangiocarcinoma. Vorasidenib created a separate neuro-oncology opportunity with a different patient journey, treatment duration and competitive requirement.

FDA approved VORANIGO (vorasidenib) in August 2024 for Grade 2 astrocytoma or oligodendroglioma carrying a susceptible IDH1 or IDH2 mutation following surgery. The pivotal INDIGO trial enrolled 331 patients. Vorasidenib reduced the risk of disease progression or death by 61% compared with placebo, corresponding to a progression-free survival hazard ratio of 0.39.

The therapeutic value is particularly relevant because these patients can be young, clinically stable and not yet in need of radiation or chemotherapy. IDH inhibition therefore creates an opportunity to intervene after surgery while delaying more intensive treatment.

European access followed in 2025. Voranigo received a marketing authorization valid throughout the European Union on September 17, 2025 for eligible Grade 2 IDH1- or IDH2-mutant astrocytoma or oligodendroglioma.

The commercial effect is already visible in Servier's financial results. The company reported €2.21 billion in oncology revenue for FY2024/25, up 54.6%, and identified higher oncology sales volume following the U.S. launch of Voranigo as an important growth contributor. Servier's U.S. subsidiary revenue increased 70.3% to €1.496 billion over the same financial year.

This changes the competitive question for IDH drug developers. CNS penetration, mutation coverage, long-duration tolerability and activity after prior IDH inhibition have become commercially significant alongside AML response rates.

FDA-Approved IDH Inhibitors: Current Commercial Product Map

The current approved market remains concentrated around four principal agents, but their commercial opportunities differ considerably. Ivosidenib has the broadest indication reach, olutasidenib competes specifically in IDH1-mutant relapsed/refractory AML, enasidenib anchors the approved IDH2 inhibitor segment and vorasidenib created the first approved dual IDH1/2 CNS treatment segment.

Isocitrate Dehydrogenase Inhibitors Market Key Takeaways

• The market is projected to increase from US$3.80 billion in 2025 to US$10.69 billion by 2035, supported by broader mutation testing and expansion beyond AML into solid tumors.
• IDH1 inhibitors lead with 52.3% of 2025 market revenue, reflecting the broader commercial reach of IDH1 targeting across AML, MDS and cholangiocarcinoma, alongside increasing IDH1 relevance in glioma.
• AML remains the largest application with 58.7% of 2025 revenue, but glioma is changing the market's growth profile after the launch of vorasidenib.
• IDH-mutant glioma has become the primary new competitive frontier. Nuvation Bio's safusidenib produced a confirmed response rate of 51.9% and a 36-month progression-free survival rate of 79.1% in updated Phase II Grade 2 IDH1-mutant glioma data, while development has expanded into Phase III and post-vorasidenib treatment.
• Frontline AML remains a major label-expansion opportunity. Servier's June 2026 pipeline includes ivosidenib with 7+3 chemotherapy and an ivosidenib-azacitidine-venetoclax regimen in AML.
• Servier has built the broadest current IDH franchise, spanning TIBSOVO and VORANIGO, while its development portfolio targets chondrosarcoma, additional AML combinations and new glioma combinations.
• Mutation testing is a commercial gatekeeper rather than an optional diagnostic step. FDA-approved IDH therapies require confirmation of susceptible IDH1 or IDH2 mutations, linking drug adoption directly with companion diagnostics and molecular pathology infrastructure.

AML Still Drives Revenue, but Glioma Is Changing the Growth Curve

Acute Myeloid Leukemia: The Commercial Foundation of IDH Inhibition

Acute myeloid leukemia accounted for 58.7% of global IDH inhibitor revenue in 2025, making it the largest application by a wide margin.

The underlying mutation frequency gives IDH therapy a clearly defined molecular population. A 2026 Blood Advances analysis of 4,113 AML cases found IDH mutations in 28% of patients, including IDH1 mutations in 10% and IDH2 mutations in 18%. The study also found IDH mutations in 6.3% of MDS and 5.2% of CMML cases.

The United States is expected to record 22,720 new AML cases and 11,500 deaths in 2026, with five-year relative survival of 33.4%. The continuing mortality burden and high molecular-testing relevance support sustained demand for targeted treatment.

Commercially, AML contains three approved IDH treatment franchises.

Ivosidenib targets mutant IDH1 and can be used in selected newly diagnosed IDH1-mutant AML, including in combination with azacitidine, as well as in relapsed/refractory disease. The AGILE study supporting the azacitidine combination enrolled 146 patients. Median overall survival reached 24.0 months with ivosidenib plus azacitidine versus 7.9 months in the comparator arm.

Olutasidenib competes in relapsed or refractory IDH1-mutant AML. FDA approval was supported by 147 patients, with a 35% CR+CRh rate and median CR+CRh duration of 25.9 months.

Enasidenib addresses IDH2-mutant relapsed or refractory AML. The registration trial included 199 adults and produced a 23% CR/CRh rate, with responses lasting a median 8.2 months.

The next commercial expansion is likely to come from moving mutation-directed treatment deeper into frontline regimens, including combinations with venetoclax, azacitidine, and intensive induction chemotherapy. Servier lists both ivosidenib plus 7+3 and ivosidenib plus azacitidine plus venetoclax within its June 2026 clinical pipeline.

Glioma Is Becoming the Fastest-Developing IDH Application

Glioma accounted for 11.3% of IDH inhibitor revenue in 2025, but its growth trajectory is materially stronger than its current share suggests.

The difference from AML is commercially important. AML-targeted agents can be used in patients with rapidly progressive disease and often require close hematology monitoring. Grade 2 IDH-mutant glioma can involve years of disease management, making oral CNS-penetrant therapy, treatment duration, and long-term safety central to product value.

Vorasidenib currently defines the approved market. It inhibits mutant IDH1 and IDH2 and was designed to penetrate the central nervous system. The FDA approval covers eligible Grade 2 astrocytoma and oligodendroglioma after surgery in patients aged 12 years and older.

The commercial opportunity is expanding beyond the initial label. Servier is developing vorasidenib plus temozolomide and vorasidenib plus pembrolizumab in glioma, showing a clear strategy to extend the franchise beyond monotherapy in surgery-treated Grade 2 disease.

Nuvation Bio is creating the strongest current competitive program. Safusidenib is an oral, brain-penetrant selective mutant IDH1 inhibitor. Its SIGMA program was expanded into a pivotal Phase III trial in February 2026 for patients with high-risk or high-grade IDH1-mutant astrocytoma after standard therapy. Enrollment was increased to 300 patients for the registrational portion.

Updated July 2026 Phase II results in chemotherapy- and radiotherapy-naïve Grade 2 IDH1-mutant glioma showed a 51.9% confirmed response rate and 79.1% progression-free survival at 36 months, with median PFS not reached after 38.8 months of follow-up.

Nuvation Bio also announced a new Phase II study specifically for patients whose IDH1-mutant glioma progresses after treatment with vorasidenib. This is strategically important because it begins to define a post-Voranigo treatment market, something that did not exist before the first commercial IDH glioma therapy entered clinical practice.

Cholangiocarcinoma Remains the Second-Largest Application

Cholangiocarcinoma accounted for 22.4% of the IDH inhibitor market in 2025, making it the second-largest application after AML.

Ivosidenib became the first major commercial IDH-targeted treatment in this solid-tumor setting when FDA approved it in August 2021 for previously treated locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation.

The next competitive objective is moving IDH1 inhibition earlier in treatment. Servier's current pipeline includes ivosidenib with durvalumab plus gemcitabine/cisplatin in cholangiocarcinoma, which would place mutant IDH1 blockade alongside immunotherapy and standard chemotherapy rather than reserving it solely for previously treated disease.

This development has significant commercial implications. Successful earlier-line use would expand treatment duration and increase the number of IDH1-mutant cholangiocarcinoma patients exposed to targeted therapy before multiple lines of treatment reduce performance status.

MDS and Chondrosarcoma Are the Most Credible New Indication Opportunities

IDH1-Mutant Myelodysplastic Syndromes

FDA approved TIBSOVO in October 2023 for adults with relapsed or refractory MDS carrying a susceptible IDH1 mutation. It was the first targeted therapy approved for this molecularly selected MDS population.

The registration study included 18 patients and produced a 38.9% complete-remission rate. Six of nine patients who were transfusion-dependent at baseline achieved red-cell and platelet transfusion independence during a qualifying post-baseline period.

The opportunity remains larger than the existing relapsed/refractory label. The 2026 Blood Advances cohort found IDH mutations in 6.3% of MDS cases, including 1.8% with IDH1 and 4.6% with IDH2 mutations.

Continued development in earlier MDS settings could therefore extend the IDH market beyond AML while leveraging the same hematology testing and treatment infrastructure.

IDH1-Mutant Chondrosarcoma

Chondrosarcoma represents a different kind of white-space opportunity because advanced disease has limited effective systemic treatment.

Servier's CHONQUER Phase III trial is evaluating ivosidenib against placebo in adults with locally advanced or metastatic conventional chondrosarcoma carrying an IDH1 mutation. The study operates across 114 locations and includes patients who have received no more than one prior systemic regimen.

A positive Phase III result would give ivosidenib another rare solid-tumor indication and strengthen Servier's strategy of building one mutant-IDH platform across hematologic malignancies, biliary tract cancer and molecularly defined sarcomas.

IDH1 vs IDH2 vs Dual Inhibitors: Segment Analysis

IDH1 Inhibitors Hold 52.3% of Market Revenue

IDH1 inhibitors accounted for 52.3% of global IDH inhibitor revenue in 2025, making them the largest target segment.

The segment benefits from greater indication breadth. Ivosidenib participates in AML, MDS and cholangiocarcinoma, while olutasidenib provides another IDH1-targeted option in relapsed/refractory AML. IDH1 is also the principal mutation targeted by several emerging glioma programs.

Commercially, IDH1 has therefore become more than an AML target. It now supports an ecosystem spanning hematology, biliary oncology, neuro-oncology and rare solid tumors.

Servier's pipeline reinforces that breadth. Ivosidenib is being developed in chondrosarcoma and new AML and cholangiocarcinoma combinations, while the company is using its broader IDH platform to extend targeting into CNS tumors through vorasidenib.

IDH2 Inhibitors Hold 38.4%

IDH2 inhibitors represented 38.4% of the market in 2025.

The approved segment is more concentrated because enasidenib remains the principal commercially established selective IDH2 inhibitor. Its current U.S. indication is adult relapsed or refractory AML with an IDH2 mutation confirmed by an FDA-approved test.

The 2026 myeloid-neoplasm study found IDH2 mutations in 18% of AML, compared with 10% for IDH1, demonstrating that the molecular patient population itself is substantial even though the commercial label landscape remains narrower.

This creates a notable white space: future IDH2 products or combinations that move successfully into newly diagnosed AML or MDS could materially change the competitive balance.

Dual IDH1/IDH2 Inhibitors Hold 9.3% but Have the Strongest Expansion Potential

Dual IDH1/2 inhibitors accounted for 9.3% of market revenue in 2025.

The segment is currently defined commercially by vorasidenib. Unlike selective AML-focused inhibitors, vorasidenib addresses both susceptible IDH1 and IDH2 mutations in Grade 2 glioma and is designed for CNS exposure.

The segment's relatively small current share therefore understates its strategic importance. Dual mutation coverage combined with brain penetration gives it access to a patient population that selective hematology-focused inhibitors were not designed to serve.

Mutation Testing Is Part of the Market, Not a Pre-Treatment Detail

Every major IDH inhibitor franchise depends on molecular confirmation.

FDA approved the Abbott RealTime IDH1 Assay alongside olutasidenib to identify eligible patients with IDH1-mutant AML. An FDA-approved IDH2 test is similarly required for enasidenib, and the IDH1 assay is used in multiple IDH1-targeted treatment pathways.

For vorasidenib, mutation status in INDIGO was prospectively established using the Oncomine Dx Target Test. This ties neuro-oncology drug adoption to molecular pathology capability in much the same way that IDH testing is already embedded in AML treatment selection.

The commercial value of diagnostic infrastructure grows as IDH therapy enters additional indications. A hospital that can rapidly distinguish IDH1, IDH2 and wild-type tumors can connect patients to approved treatment, clinical trials and subsequent molecularly defined therapy without repeating the entire diagnostic pathway.

For buyers, this means the IDH inhibitor market should be assessed together with companion diagnostics, next-generation sequencing, tumor pathology and molecular monitoring, particularly as treatment moves into earlier disease.

Market Growth Drivers

Precision Oncology Is Increasing Identification of Eligible Patients

IDH inhibitor demand is inherently dependent on identifying mutant disease. Broader use of next-generation sequencing and companion diagnostics therefore increases the addressable treated population even when total cancer incidence is unchanged.

The importance of testing is particularly clear in AML. A large 2026 molecular cohort found that 28% of AML cases carried IDH1 or IDH2 mutations, with distinct mutation frequencies and co-mutation patterns that can influence treatment decisions.

As genomic profiling becomes routine across academic and community oncology networks, fewer IDH-mutant patients are likely to remain unidentified.

Expansion Into Earlier Treatment Lines

The current market includes several relapsed/refractory labels. Moving targeted therapy earlier creates a larger commercial population.

The strongest validated example is newly diagnosed IDH1-mutant AML in selected older or medically unfit adults. Ivosidenib plus azacitidine produced a major overall-survival improvement over azacitidine-based control treatment in AGILE.

Current development with 7+3 induction chemotherapy and azacitidine-venetoclax combinations seeks to broaden IDH targeting further into frontline AML.

CNS Penetration Opens a New Oncology Category

Vorasidenib established that a mutant IDH inhibitor designed for CNS exposure can delay progression in Grade 2 IDH-mutant glioma.

Nuvation Bio's safusidenib program is expanding the same commercial concept into high-risk and high-grade IDH1-mutant astrocytoma and post-vorasidenib disease.

CNS penetration is therefore becoming a key product-development criterion rather than a secondary pharmacologic characteristic.

Combination Treatment Expands Franchise Value

Servier is testing ivosidenib alongside intensive AML chemotherapy, venetoclax-based treatment and a durvalumab-chemotherapy backbone in cholangiocarcinoma. It is also developing vorasidenib with temozolomide and pembrolizumab in glioma.

This strategy can extend the same IDH drug franchise across treatment lines rather than relying only on monotherapy in a narrow molecular subset.

Commercial Constraints and Development Risks

Small Molecular Subpopulations Limit Volume

IDH inhibitors benefit from high biomarker specificity but face a natural ceiling on patient volume.

Even in AML, where IDH mutations were found in 28% of patients in a recent large cohort, each individual mutation class represents only part of the total disease population. IDH1 accounted for 10% and IDH2 for 18%.

Drug developers therefore need either strong value per treated patient, multiple indications or both to build a large franchise.

Differentiation Syndrome Requires Active Management

Differentiation syndrome is a clinically important class issue for IDH inhibitors used in AML.

FDA labeling for olutasidenib includes a boxed warning because differentiation syndrome can be fatal. Enasidenib and ivosidenib treatment pathways also require clinicians to recognize and manage this complication promptly.

This reinforces the commercial importance of experienced hematology centers and structured toxicity-management protocols.

CNS Treatment Introduces Different Safety Requirements

Vorasidenib has a different safety-management profile from AML-focused inhibitors. Liver-enzyme elevations are an important concern, and current labeling requires scheduled liver-function monitoring during therapy.

Long treatment durations in patients with Grade 2 glioma mean safety, adherence, and chronic monitoring can affect real-world persistence.

Resistance Will Become More Important as Treatment Moves Earlier

The first generation of commercial IDH glioma treatment has now created a future population whose tumors may progress after prior IDH inhibition.

Nuvation Bio's planned Phase II study in patients progressing after vorasidenib is an early sign that post-IDH-inhibitor sequencing is becoming a distinct clinical-development area.

For investors, activity after prior IDH therapy could become one of the strongest differentiators among future CNS assets.

Regional and Country-Level Commercial Analysis

North America: 44.6% of Global Revenue

North America accounted for 44.6% of global IDH inhibitor revenue in 2025, making it the largest regional market. The United States represented more than 85% of North American revenue in the cited market benchmark.

The region combines early FDA approvals, widespread molecular-testing infrastructure, and a concentration of academic hematology, and neuro-oncology centers.

The United States is expected to record 22,720 new AML cases in 2026. A current molecular study found IDH1 or IDH2 alterations in 28% of AML samples, demonstrating why AML mutation testing remains commercially central to the U.S. IDH inhibitor market.

The United States also became the first commercial market for vorasidenib in Grade 2 IDH-mutant glioma in August 2024. Servier later reported a strong increase in U.S. oncology sales volume following the launch.

For buyers, the most attractive U.S. opportunities through 2035 are likely to be earlier-line AML combinations, next-generation glioma therapy, post-vorasidenib sequencing and companion diagnostic expansion.

Europe: 26.8% of Global Revenue

Europe represented 26.8% of global IDH inhibitor revenue in 2025, making it the second-largest commercial region.

The region's competitive position strengthened when Voranigo received EU-wide marketing authorization on September 17, 2025. The European indication covers eligible adults and adolescents aged 12 years and older with predominantly non-enhancing Grade 2 IDH1 R132- or IDH2 R172-mutant astrocytoma or oligodendroglioma following surgery when immediate radiation or chemotherapy is not required.

Germany, France, Italy, Spain and other major European oncology markets therefore now have access to an approved IDH-directed glioma therapy in addition to established hematology and cholangiocarcinoma treatment pathways.

The commercial challenge in Europe is likely to center on demonstrating durable value over years of treatment, particularly in Grade 2 glioma where patients can live for long periods and health systems must evaluate the value of delaying radiation and chemotherapy.

Asia-Pacific: Fastest-Growing Regional Opportunity

Asia-Pacific is the fastest-growing IDH inhibitor market, supported by expanding molecular diagnostics, oncology treatment capacity, and participation in global targeted-therapy trials.

China has become strategically important not only because of patient volume but because it is increasingly included in global IDH drug development. Nuvation Bio's pivotal SIGMA safusidenib program includes sites in the United States, Australia and China and is designed to support regulatory submissions for IDH1-mutant astrocytoma.

Australia is also participating in the same global trial program, showing how the neuro-oncology pipeline is becoming more geographically diversified than the original U.S.-focused IDH commercial market.

For Asia-Pacific buyers, the long-term opportunity lies in increasing access to mutation testing first, followed by broader adoption of premium oral targeted treatments as reimbursement develops.

Latin America: 6.8% Market Share

Latin America accounted for 6.8% of global IDH inhibitor revenue in 2025.

Brazil and Mexico are the principal commercial markets within the region because of their large oncology populations and concentration of advanced molecular testing in major private and academic cancer centers.

The opportunity remains access-led. Wider use of IDH inhibitors depends on expanding molecular profiling outside the largest tertiary institutions, ensuring specialty-drug reimbursement and connecting mutation-positive patients with targeted treatment before disease progression limits eligibility.

Middle East and Africa: 4.0% Market Share

The Middle East and Africa accounted for 4.0% of global IDH inhibitor revenue in 2025.

Gulf healthcare systems offer the strongest near-term opportunity for premium IDH-targeted treatment because advanced genomic testing and specialty oncology medicines are increasingly concentrated in major tertiary centers.

Across broader African markets, the principal limitation is not the scientific relevance of IDH inhibition but access to genomic classification and specialist hematology or neuro-oncology care.

Company Positioning: A Concentrated Market With a Clear Franchise Leader

Servier: Multi-Indication IDH Franchise Leadership

Servier holds the broadest current commercial position through TIBSOVO and VORANIGO.

TIBSOVO gives the company exposure to AML, MDS and cholangiocarcinoma, while VORANIGO creates a separate glioma franchise. FDA and EU approvals make the company active in both hematologic and solid-tumor IDH treatment.

Commercial performance supports the strategy. Servier reported €2.21 billion in oncology revenue in FY2024/25, up 54.6%, and directly linked the increase in oncology sales volume to the U.S. Voranigo launch.

Servier's current IDH pipeline is also wider than its approved portfolio. It includes:

• Ivosidenib in Phase III chondrosarcoma development.
• Ivosidenib with durvalumab and gemcitabine/cisplatin in cholangiocarcinoma.
• Ivosidenib with 7+3 chemotherapy in AML.
• Ivosidenib with azacitidine and venetoclax in AML.
• Vorasidenib with temozolomide in glioma.
• Vorasidenib with pembrolizumab in glioma.

This creates a franchise-development model based on indication expansion and combinations, rather than relying on a single approved molecular niche.

Rigel Pharmaceuticals: Focused IDH1 AML Competition

Rigel markets REZLIDHIA (olutasidenib) in the United States for adults with relapsed or refractory IDH1-mutant AML.

The product remains much smaller commercially than Servier's broader oncology franchise but is growing. Rigel reported US$31.0 million in REZLIDHIA net product sales in 2025, up 35% from US$23.0 million in 2024.

The commercial position is differentiated by the drug's dedicated relapsed/refractory IDH1 AML indication and durable response data. FDA reported a 35% CR+CRh rate and median CR+CRh duration of 25.9 months at approval.

For Rigel, the key growth question is whether olutasidenib can extend beyond its current U.S. relapsed/refractory AML base through wider geographic commercialization or additional hematologic settings.

Bristol Myers Squibb: The Established IDH2 Position

Bristol Myers Squibb's IDHIFA (enasidenib) remains the established selective IDH2 inhibitor for adults with relapsed or refractory IDH2-mutant AML.

The molecular opportunity is meaningful. IDH2 mutations were present in 18% of AML cases in the 4,113-patient AML cohort published in 2026, exceeding the 10% frequency observed for IDH1 in that dataset.

The commercial gap lies in label breadth. The current approved IDH2 market remains more concentrated in relapsed/refractory AML than the IDH1 segment, giving future frontline or MDS-focused IDH2 strategies room to reshape competition.

Nuvation Bio: The Main Emerging Glioma Challenger

Nuvation Bio has become one of the most important companies to monitor because safusidenib directly addresses the fastest-developing part of the market.

The drug is a brain-penetrant selective mutant IDH1 inhibitor. Its global Phase III SIGMA program covers high-risk and high-grade IDH1-mutant astrocytoma after standard therapy.

July 2026 data strengthened the commercial case in lower-grade disease, with a 51.9% confirmed response rate and 79.1% 36-month PFS rate among chemotherapy- and radiotherapy-naïve Grade 2 IDH1-mutant glioma patients.

The company is also opening two strategically distinct markets: newly diagnosed Grade 2 glioma outside the United States and treatment after progression on vorasidenib in the United States.

If successful, safusidenib could compete not only for untreated IDH1-mutant glioma but also establish the first clear commercial sequence after VORANIGO.

Pipeline Opportunities Most Likely to Change the Market

1. Safusidenib in High-Risk and High-Grade Glioma

The Phase III SIGMA program addresses Grade 2 astrocytoma with high-risk features and Grade 3 or Grade 4 IDH1-mutant astrocytoma following standard therapy. This differs from VORANIGO's current Grade 2 post-surgical population and could therefore expand targeted therapy into higher-risk disease rather than simply compete within the existing label.

2. Post-Vorasidenib IDH1-Mutant Glioma

Nuvation Bio's planned Phase II study following vorasidenib progression creates a new commercial category: treatment after resistance or progression on an approved CNS IDH inhibitor.

This could become increasingly important as the number of patients receiving VORANIGO grows.

3. Ivosidenib in Chondrosarcoma

CHONQUER is testing ivosidenib in IDH1-mutant conventional chondrosarcoma where effective systemic options remain limited. The global Phase III program has 114 locations.

A successful outcome would further diversify IDH1 inhibitor revenue away from hematology.

4. Frontline AML Combination Therapy

Servier is developing ivosidenib with 7+3 chemotherapy and with azacitidine plus venetoclax.

The strategic value is high because success could increase IDH inhibitor exposure among younger or fitter newly diagnosed patients who currently fall outside the narrower older/unfit ivosidenib-azacitidine population.

5. First-Line Cholangiocarcinoma Combination Therapy

Ivosidenib plus durvalumab and gemcitabine/cisplatin is being developed in IDH1-mutant cholangiocarcinoma.

This could shift IDH-targeted treatment from a post-progression strategy to part of the initial systemic-treatment pathway.

6. Vorasidenib Combinations

Vorasidenib is being studied with both temozolomide and pembrolizumab.

Successful combinations would allow Servier to extend an approved Grade 2 glioma franchise into patients requiring more intensive treatment.

IDH Inhibitors Market Scope

Buyer and Investment Evaluation Criteria

Mutation Coverage

A product targeting IDH1 alone competes in a different patient population from an IDH2 or dual inhibitor. Mutation frequency, eligible variants and diagnostic requirements therefore need to be assessed before total cancer incidence.

CNS Penetration

For glioma assets, brain penetration has become a core commercial requirement. Vorasidenib validated the concept, while safusidenib is being developed specifically as a brain-penetrant mutant IDH1 inhibitor.

Position in the Treatment Journey

Earlier use generally increases the addressable population. The commercial opportunity for an AML asset used only after relapse differs significantly from an agent that can be integrated into newly diagnosed treatment.

Combination Compatibility

Future IDH inhibitors increasingly need to integrate with azacitidine, venetoclax, intensive chemotherapy, temozolomide, immunotherapy or other established treatment platforms. Servier's current development portfolio illustrates how combination compatibility is becoming a central franchise strategy.

Activity After Prior IDH Therapy

As approved IDH inhibitors gain adoption, treatment after resistance will become more relevant. The new post-vorasidenib safusidenib study provides an early example of how this market can develop.

Diagnostic Infrastructure

Drug availability alone does not create adoption. Hospitals need rapid molecular testing capable of identifying IDH1, IDH2 and relevant variants before targeted treatment can begin. FDA-approved companion diagnostics are already embedded in several commercial indications.

Safety and Monitoring

Differentiation syndrome remains a major consideration in AML, while liver toxicity monitoring is important with vorasidenib. Buyers must assess the operational cost of monitoring alongside drug acquisition price.

Recent Developments in the IDH Inhibitors Market

July 2026 - Safusidenib Program Expands

Nuvation Bio reported updated Phase II Grade 2 IDH1-mutant glioma results showing a 51.9% confirmed response rate and 79.1% 36-month PFS rate. The company also announced new studies in untreated Grade 2 glioma outside the United States and in patients progressing after vorasidenib.

June 2026 - Servier Expands IDH Combination Pipeline

Servier's June 2026 development pipeline includes new AML, cholangiocarcinoma and glioma combinations involving ivosidenib and vorasidenib, alongside Phase III development of ivosidenib in chondrosarcoma.

February 2026 - SIGMA Becomes a Pivotal Phase III Study

Nuvation Bio expanded SIGMA from Phase II into a global Phase III registrational trial with a planned 300-patient pivotal population in high-risk and high-grade IDH1-mutant astrocytoma.

January 2026 - Servier Reports Strong Oncology Growth

Servier reported €2.21 billion in FY2024/25 oncology revenue, an increase of 54.6%, with the U.S. Voranigo launch contributing to higher oncology sales volumes.

September 2025 - Voranigo Receives EU Authorization

Voranigo received European Union marketing authorization for eligible Grade 2 IDH1- or IDH2-mutant astrocytoma and oligodendroglioma on September 17, 2025.

August 2024 - FDA Approves the First Systemic Therapy for Grade 2 IDH-Mutant Glioma

FDA approved vorasidenib following INDIGO, creating the first commercial IDH1/2 inhibitor market in Grade 2 astrocytoma and oligodendroglioma.